X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HRP-12975 is the first novel disease-modifying chemical entity discovered with any brain organoid discovery platform and thus represents an industry first and validation for the approach of human-led in vitro experimental drug discovery.
Lead Product(s): HRP-12975
Therapeutic Area: Genetic Disease Product Name: HRP-12975
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rett Syndrome Research Trust
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2023
Details:
The findings further demonstrate the emerging role the neuroimmune axis may play in the development of schizophrenia and in providing a platform for schizophrenia drug discovery.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cerevel Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
